Tiragolumab, CAS 1918185-84-8

Product Description: Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC)[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. /[2]Caruso C. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10(8):1086-1087.

CAS Number: 1918185-84-8

Molecular Weight: N/A

Compound Purity: 99.04

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: Others

• Artikelnummer: MEXHY-P9986-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9986-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated